CCR5 Antagonists and Tropism Testing in Clinical Practice

ACTIVITY LINKS Accreditation Info Required Materials Disclosures Learning Objectives Instructions for Credit Privacy Policy

This continuing-education activity consists of one 77-minute podcast (or the written summary; see Required Materials section below), an accompanying slide set and a post-test consisting of 5 questions. The full activity should take approximately 86 minutes to complete. Once you have listened to the podcast or read the written summary, scored 70% or higher on this activity's post-test and completed the post-test evaluation, you will be eligible to receive:

• Physicians: Up to 1.5 hours of AMA PRA category 1 credit.
• Pharmacists: Up to 1.5 hours of pharmacy credit.
• Registered Nurses: Up to 1.5 hours of Nursing Continuing Education contact credit (or 1.8 hours of California Board of Registered Nursing credit).

This activity was released on October 14, 2008. Credit for successfully completing this activity will be available until October 14, 2009.

Unsure if you can earn credit for this activity? Read the "Credit information for ..." sections for more information.

Joint-Sponsorship Information

This activity is jointly sponsored by Postgraduate Institute for Medicine and The Body PRO.

For information about the accreditation of this program, please contact PIM at 303.799.1930 or information@pimed.com.

This continuing-education activity is funded by educational grants from Pfizer Inc. and Monogram Biosciences, Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and The Body PRO. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing-education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number: 809-999-08-229-H02-P)

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 8 weeks (if applicable).

Nursing Continuing Education

CNA/ANCC: This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine (PIM).

PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

California Board of Registered Nursing: Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.8 contact hours.

Fee Information

There is no fee for this educational activity.

At the heart of this activity is a research summary available in two different formats: MP3 audio and a written transcript. You can use either of these two formats to complete this activity.

In addition to the audio/written summary, an accompanying slide set is also provided, and is required material for this activity.

Read/Listen to This Activity

• Read Written Summary (includes links to audio and slides)
• Listen to Podcast (77 min.)
• Download PowerPoint Slide Set
• Listen to Audio With Slides

Written Summaries, Audio and Slides Divided by Topic

• Research Update
  Read Written Summary
  Listen to Podcast (45 min.)
  Download Slides
• Case Studies
  Read Written Summary
  Listen to Podcast (33 min.)
  Download Slides

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

David Hardy, M.D., has received grants or research support from Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Pfizer, and Tibotec. He has served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Monogram, Pfizer, and Tibotec. He has received fees for non-CME services from Gilead Sciences, Pfizer, and Tibotec. He owns stock in Merck.

Click here for a brief biography of Dr. Hardy.

PIM Clinical Reviewers Jan Hixon, R.N., B.S.N., M.S.N.; Trace Hutchison, Pharm.D.; and Linda Graham, R.N., B.S.N., have no real or apparent conflicts of interest to disclose.

The planner and editor of this program, Bonnie Goldman, Editorial Director of TheBodyPRO.com, has no significant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), The Body PRO, Pfizer Inc. and Monogram Biosciences, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, The Body PRO, Pfizer Inc. and Monogram Biosciences, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Purpose:

The purpose of this activity is to provide HIV physicians, pharmacists, nurses and other health care professionals with the opportunity to supplement their knowledge on issues related to the use of CCR5 antagonists and tropism testing in HIV-infected patients.

Target Audience:

This activity has been designed to meet the educational needs of physicians, pharmacists, registered nurses and other health care professionals involved in the care of patients with HIV.

Objectives:

Participants who complete this educational activity should be able to:

1. Outline the findings of recent, key research regarding CCR5 antagonists that have been approved by the U.S. Food and Drug Administration or are in active development.
2. Review the differences between CCR5-tropic HIV and CXCR4-tropic HIV.
3. Explain the importance of tropism testing in the effective treatment of HIV-infected patients.
4. Identify optimal strategies for the incorporation of CCR5 antagonists into antiretroviral therapy.

This activity is no longer available for CME/CE credit.